Targeting the Menin–KMT2A Axis in AML: Translating Molecular Insights into Therapeutic Success
Clinical Lymphoma Myeloma and Leukemia · 2026-10 · 26 (10) · 649-660
DOI: 10.1016/j.clml.2026.07.019 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-10. Verfasst von Claudia Simio und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology-Oncology, Azienda Universitaria Ospedaliera Renato Dulbecco, Catanzaro, Italy. Electronic address: claudia92simio@gmail.com. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myeloid-Lymphoid Leukemia Protein, Proto-Oncogene Proteins, Histone-Lysine N-Methyltransferase. Die Arbeit nennt 41 Literaturangaben.
Abstract (Originalsprache)
Menin inhibitors (MIs) represent a novel class of targeted agents that disrupt the interaction between the nuclear protein menin and the KMT2A (MLL) complex, thereby interrupting a crucial oncogenic transcriptional program in acute myeloid leukemias (AML) with KMT2A rearrangements and NPM1 mutations. Robust preclinical data have shown that menin inhibition suppresses HOXA/MEIS1 expression, induces differentiation, and reduces the fitness of leukemic cells, including the stem-like compartment. These findings rapidly led to phase I/II clinical trials with oral MIs such as revumenib and ziftomenib, which demonstrated CR+CRh rates of 22% to 23% in refractory/relapsed patients, with conversion to measurable residual disease (MRD) negativity in 61% to 68% of responders and early use as a bridge to allogeneic transplantation. However, the median duration of response remains limited (approximately 4-5 months), suggesting that menin inhibition as monotherapy may be insufficient to ensure durable disease control. Key emerging clinical issues include specific adverse events (QTc prolongation in 12%-44%, differentiation syndrome in 10%-29%), drug-drug interactions mediated by CYP3A4 metabolism, resistance dynamics (on-target mutations in 39% of cases), and the definition of the optimal role in combination with venetoclax, hypomethylating agents, and intensive chemotherapy. This review synthesizes molecular mechanisms, preclinical and clinical data, discusses use within MRD-guided and transplant pathways, and proposes translational priorities for integrating MIs into future therapeutic paradigms, pending confirmation from randomized studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology-Oncology, Azienda Universitaria Ospedaliera Renato Dulbecco, Catanzaro, Italy. Electronic address: claudia92simio@gmail.com.
- Hématologie Adultes, Hôpital Saint Louis, Paris, France.
Zitieren
APA
Simio, C., & Vatteroni, A. (2026). Targeting the Menin–KMT2A Axis in AML: Translating Molecular Insights into Therapeutic Success. Clinical Lymphoma Myeloma and Leukemia, 26(10), 649-660. https://doi.org/10.1016/j.clml.2026.07.019
Vancouver
Simio C, Vatteroni A. Targeting the Menin–KMT2A Axis in AML: Translating Molecular Insights into Therapeutic Success. Clinical Lymphoma Myeloma and Leukemia. 2026;26(10):649-660. doi:10.1016/j.clml.2026.07.019
BibTeX
@article{Simio2026,
author = {Simio, Claudia and Vatteroni, Alessandra},
title = {Targeting the Menin–KMT2A Axis in AML: Translating Molecular Insights into Therapeutic Success},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
volume = {26},
number = {10},
pages = {649--660},
doi = {10.1016/j.clml.2026.07.019}
}
EUVIMED